Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
GRB2 Biologics Sequence Review Report 2026: Growth factor receptor-bound protein 2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of GRB2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GRB14 Biologics Sequence Review Report 2026: Growth factor receptor-bound protein 14 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of GRB14 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GRB10 Biologics Sequence Review Report 2026: Growth factor receptor-bound protein 10 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of GRB10 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FRS2 Biologics Sequence Review Report 2026: Fibroblast growth factor receptor substrate 2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of FRS2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FCMR Biologics Sequence Review Report 2026: Immunoglobulin mu Fc receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of FCMR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FRS3 Biologics Sequence Review Report 2026: Fibroblast growth factor receptor substrate 3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of FRS3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GPA33 Biologics Sequence Review Report 2026: Cell surface A33 antigen Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of GPA33 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FCAR Biologics Sequence Review Report 2026: Immunoglobulin alpha Fc receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of FCAR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FCER2 Biologics Sequence Review Report 2026: Low affinity immunoglobulin epsilon Fc receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of FCER2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FCGR1BP Biologics Sequence Review Report 2026: Putative high affinity immunoglobulin gamma Fc receptor IB Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of FCGR1BP protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FCER1A Biologics Sequence Review Report 2026: High affinity immunoglobulin epsilon receptor subunit alpha Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of FCER1A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FAS Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 6 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of FAS protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
114
115
116
117
118
>>
1670
>